Figure_4.tif (617.14 kB)
Download file

Depletion of neutrophils ameliorates autoimmune disease.

Download (0 kB)
posted on 10.07.2014, 03:01 by Christine M. Coquery, Nekeithia S. Wade, William M. Loo, Jason M. Kinchen, Kelly M. Cox, Chao Jiang, Kenneth S. Tung, Loren D. Erickson

B6.Faslpr/JTnfrsf17−/−mice were treated with the 1A8 neutrophil depleting antibody or a control antibody. After 4 weeks, sera, kidney and spleen were analyzed for markers of autoimmune disease. (A) Representative flow cytometry plots showing reduced frequency of neutrophils (CD11b+GR1+) in spleens after treatment. One plot from 5 mice/group is shown. (B, C) Serum BAFF and IFNγ levels were measured after treatment by ELISA. Combined data from 5 mice/genotype. (D) Total numbers of CD4+ T cells and IFNγ-producing CD4+ T cells were quantified from spleens of mice after treatment. Combined data from 5 mice/group. (E) Total numbers of B cells, GC B cells (CD19+GL7+CD138), and PCs (CD19+/lowCD138+) in spleens of mice after treatment were determined by flow cytometry. (F) Serum dsDNA IgG titers of mice before and after treatment were determined by ELISA. Each symbol represents the fold change of autoantibody titers from an individual mouse after treatment. (G) IgG and C3 deposition in kidneys of mice was measured after treatment. One representative image from 5 mice/group is shown. (A–G) One of two independent experiments with similar results is shown. Error bars indicate mean ± SEM. Statistics determined with a Student’s t test (B–E), or a two-way ANOVA using Bonferroni post test (F), and denoted as follows: *p<0.05, **p<0.01.